Division of Cancer Sciences

Search results

• Access to more effective therapies in Non-Hodgkin Lymphoma

  Illidge, T. (Corresponding participant), Radford, J. (Participant) & Honeychurch, J. (Participant)

  Impact: Health and wellbeing, Economic

• Adjuvant therapy in melanoma adopted as standard of care

  Lorigan, P. (Participant)

  Impact: Health and wellbeing

• A phase II study of conformal hypofractionated radiotherapy with concurrent gemcitabine (GemX) in muscle-invasive bladder cancer.

  Choudhury, A. (Participant)

  Impact: Health impacts

• A restatement of the natural science evidence base concerning the health effects of low-level ionizing radiation

  Hoskin, P. (Participant), McLean, A. R. (Participant), Adlen, E. K. (Participant), Cardis, E. (Participant), Goodhead, D. T. (Participant), Harms-Ringdahl, M. (Participant), Hendry, J. (Participant), Jeggo, P. A. (Participant), Mackay, D. (Participant), Muirhead, C. R. (Participant), Shepherd, J. (Participant), Shore, R. E. (Participant), Thomas, G. (Participant), Wakeford, R. (Participant) & Godfray, H. C. J. (Participant)

  Impact: Health impacts

• Chair of ESMO GU oncology guidelines

  (Participant)

  Impact

• Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer (ABC-02). N Engl J Med 362(14): 1273-81

  Valle, J. (Corresponding participant)

  Impact: Health impacts, Societal impacts

• Clinical research leading to a new standard of care developed for the management of untreated primary CNS lymphoma

  (Participant)

  Impact: Health impacts

• Colorectal cancer: Summary of NICE guidance

  Hoskin, P. (Participant)

  Impact: Health impacts

• Commercial Development and Patient Benefit of Adoptive Cell Therapy (ACT) for Cancer

  Thistlethwaite, F. (Corresponding participant), Hawkins, R. (Participant), Stern, P. (Participant) & Gilham, D. (Participant)

  Impact: Technological impacts, Health and wellbeing, Economic, Policy

• Confirmation that prophylactic irradiation of tracts (PIT) is not justified in routine treatment of malignant pleural mesothelioma (MPM) meaning patients now do not receive unnecessary treatment

  Faivre-Finn, C. (Corresponding participant)

  Impact: Health and wellbeing

• Contributed to European Cancer Organisation (ECCO) Essential Requirements for Quality Cancer Care: Prostate cancer guidelines 2020.

  Hoskin, P. (Corresponding participant)

  Impact: Health and wellbeing

• Contribution to rapid international consensus guidelines for radiotherapy treatment during the Covid-19 pandemic to reduce risk to patients and staff

  Illidge, T. (Corresponding participant)

  Impact: Health and wellbeing

• Creation of a research database and management of patients who achieve a clinical complete response (cCR) after neoadjuvant chemo/radiotherapy for rectal cancer through surveillance in order to avoid the risks of surgery

  Renehan, A. (Corresponding participant) & Malcomson, L. (Participant)

  Impact: Health and wellbeing

• Defining immunotherapy in combination with chemotherapy as first-line treatment of patients with advanced biliary tract cancer (durvalumab)

  Valle, J. (Corresponding participant) & Mcnamara, M. (Participant)

  Impact: Health and wellbeing

• Defining the role of second-line chemotherapy for patients with advanced / inoperable biliary tract cancer (FOLFOX (oxaliplatin/5FU))

  Valle, J. (Corresponding participant)

  Impact: Health and wellbeing

• Delivery of breast radiotherapy after surgery over one week is as safe previous longer standard treatment over five weeks and benefits patients and NHS services.

  Kirwan, C. (Corresponding participant)

  Impact: Health and wellbeing, Economic

• Developing consensus guidelines on radiotherapy use during Covid-19 to reduce hospital attendances and risk of Covid infection to lung cancer patients

  Faivre-Finn, C. (Corresponding participant) & (Participant)

  Impact: Health and wellbeing

• Developing radioimmunotherapy into clinical practice- more targeted radiotherapy for lymphoma

  Illidge, T. (Corresponding participant)

  Impact: Health and wellbeing

• Developing the evidence base for a changing cervical screening programme in England

  Kitchener, H. (Participant), Dunn, G. (Participant) & Roberts, C. (Participant)

  Impact: Health impacts, Societal impacts

• Drug target for aggressive breast cancer found

  Simões, B. M. (Participant)

  Impact: Health and wellbeing

• EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer-An International Collaborative Multistakeholder Effort(†): Under the Auspices of the EAU-ESMO Guidelines Committees

  Hoskin, P. (Participant)

  Impact: Health impacts

• Establishing a standard of care treatment for biliary tract cancer patients following surgery (capecitabine)

  Valle, J. (Corresponding participant)

  Impact: Health and wellbeing

• Establishing the evidence for treatment to improve outcomes in patients with lung cancer

  Blackhall, F. (Participant), Faivre-Finn, C. (Participant), Lorigan, P. (Participant), (Participant) & (Participant)

  Impact: Health impacts

• Establishing the UK’s first high-energy proton therapy service at the Christie Hospital Manchester and University College London Hospital.

  (Participant), Appleby, R. (Participant), (Participant), Kirkby, K. (Participant) & (Participant)

  Impact: Health and wellbeing, Economic, Technological

• ESTRO ACROP consensus guideline on CT- and MRI-based target volume delineation for primary radiation therapy of localized prostate cancer

  Hoskin, P. (Participant), Salembier, C. (Participant), Villeirs, G. (Participant), De Bari, B. (Participant), Pieters, B. R. (Participant), van Vulpen, M. (Participant), Khoo, V. (Participant), Henry, A. (Participant), Bossi, A. (Participant), De Meerleer, G. (Participant) & Fonteyne, V. (Participant)

  Impact: Health impacts